Hapoalim Securities initiates coverage on Vanda Pharmaceuticals (Nasdaq: VNDA) with a Buy rating. PT $23.

Hapoalim analyst says, "VNDA is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE